Nelarabine, prodrug of arabinosylguanine (ara-G), has demonstrated T-lymphoblastic antileukemic activity in cell lines and in the clinic. To investigate the mechanism for lineage specific toxicity, the effects of ara-G were compared in CEM (T-lymphoblast), Raji (Blymphoblast), and ML-1 (myeloid) cell lines. CEM was the most sensitive to ara-G-induced apoptosis and accumulated the highest levels of ara-G triphosphate (ara-GTP). However, they incorporated less ara-G molecules into DNA; which were at internucleotide positions in all three lines. Ara-G induced an S-phase arrest in both Raji and ML-1 while in CEM, the S-phase cells decreased with a concomitant increase in the sub-G 1 population. Within 3 h of ara-G treatment, the levels of soluble (s)FasL in the medium increased significantly in CEM cultures. In parallel, an induction of FasL gene expression was observed by real-time RT-PCR. Pretreatment of CEM with a Fas antagonistic antibody, inhibited ara-G mediated cell-death. These results demonstrate that high ara-GTP accumulation in T-cells results in an S-phase-dependent apoptosis induced by ara-G incorporation into DNA, which may lead to a T-cell specific signal for the induction and liberation of sFasL. Subsequently, the sFasL induces an apoptotic response in neighboring non-S-phase cells. In contrast, myeloid and B-cells accumulated lower levels of ara-GTP and arrested in S-phase, blocking any apoptotic signaling.
Introduction
The discovery of purine nucleoside phosphorylase (PNP) deficiency, a naturally occurring disease, and the elucidation of its pathophysiology provided the rationale for the development of deoxyguanosine (dGuo) analogs as it was revealed that T-cells and B-cells responded differently to the derangement of purine metabolism. Specifically, the absence of PNP, the enzyme responsible for the catabolism of dGuo, manifests as a profound dGuo triphosphate (dGTP)-mediated T-cell lymphopenia without concomitant decrease in B-cells [1] [2] [3] [4] [5] [6] . Mechanistically, elevated levels of dGTP in T-cells resulted in a dGTP-mediated inhibition of DNA synthesis and cell-death 3, 7, 8 . Taken together, these data provided a rationale for the development of PNP inhibitors or PNP-resistant dGuo analogs, such as ara-G for the treatment of leukemias in general and T-cell acute lymphoblastic leukemia (T-ALL) in particular [9] [10] [11] .
The proximal cytotoxic metabolite of ara-G is its 5'-triphosphate, ara-GTP. The rate limiting-step in the formation of ara-GTP is the initial conversion to monophosphate by both dCyd kinase and dGuo kinase 12 . Several studies demonstrated that ara-G was specifically toxic to normal T-cells [13] [14] [15] and malignant T-lymphoid cells compared to non-T, non-B (null) cells or B lymphoid cells [16] [17] [18] [19] [20] . Consistent with the cell line data, the toxicity of ara-G in freshly isolated primary leukemia cells showed T-lymphoblast selectivity 17 . The differential accumulation and consequent selective cytotoxicity was postulated to be due to the higher phosphorylation and slower elimination of ara-GTP. Clinical investigations in humans using nelarabine (compound GW506U78, a prodrug of ara-G), also demonstrated a T-lymphoid lineage specific accumulation of ara-GTP during therapy 21, 22 . This was associated with clinical responses in this patient population suggesting a role of ara-GTP in T-cell selective cytoreductiveness.
For personal use only. on . by guest www.bloodjournal.org From 4 Similar to other nucleoside analogues [13] [14] [15] [23] [24] [25] [26] [27] [28] , the cytotoxicity of ara-GTP is dependent on incorporation of the fraudulent nucleotide into DNA 29 . For this incorporation, intracellular ara-GTP competes with its native endogenous nucleotide, dGTP 30 . After incorporation, DNA primers containing ara-GTP are resistant to further elongation resulting in an effective chain termination in vitro 31 . This replication block by incorporated ara-G results in inhibition of DNA synthesis 9, 16, 32 and death of the target cell 29 .
Based on these data, we hypothesized that the T-cell selective cytotoxicity of ara-G
should be related to quantitative and qualitative differences in incorporation of ara-G residues into DNA. For example, the number of ara-GMP molecules in DNA may be higher in T-cells and the location of these moieties into DNA may vary between cell types. Furthermore, because the incorporation of ara-G into DNA was dependent on S-phase population, cell-cycle specific differences may be associated with the observed T-cell hypersensitivity. Finally, in addition to S-phase specific cell-death, additional determinants may be responsible for lineage-specific cytotoxicity. The present work was conducted to elucidate the mechanisms that account for the observed differences in response to ara-G treatment in cell lines. 
Methods

Cell lines
5
Mycoplasma by using a commercially available kit and following the manufacturer's recommendations (Gen-Probe Inc., San Diego, CA).
Cell proliferation assays
Cells were incubated with the desired concentration of ara-G (R. I. Chemicals, Inc., Orange, CA) for 3 h and washed three times in warmed drug-free medium before assaying. For the growth inhibition assay, cells were allowed to grow for 72 h, counted on a Coulter counter (Coulter Electronics, Miami, FL), and expressed as a percent of control. For MTS assay, cells were allowed to grow for 72 h, MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium] reagent (Promega, Madison, WI) was added and the absorbance was measured at 490 nm (Dynatech, Chantilly, VA). For clonogenicity, cells were embedded in 0.35% agar and after ten days the colonies were stained with 0.02% p-iodo-nitrotetrazolium violet for 24 h. Colonies composed of more than 50 cells were scored and results were expressed as a percentage of colonies formed in untreated samples. Cloning efficiency ranged from 30% -47%.
Accumulation and elimination of ara-GTP
Exponentially growing cells were incubated with ara-G for the indicated concentrations and times. To determine the kinetics of ara-GTP elimination, cells were incubated with 100 µM ara-G for 3 hours, washed three times in medium, and then resuspended to 1 x 10 5 cells/ml. At various times aliquots were taken and the cells were pelleted. Nucleotides were extracted from cell pellet using perchloric acid method and analyzed by high pressure liquid chromatography (HPLC) 29 . The intracellular concentrations of nucleotides and ara-GTP in the extracts were calculated from a given number of cells of a determined mean cell volume (Coulter channelizer, Coulter Electronics, Inc.). This calculation assumes the nucleotides are uniformly distributed in
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Effect of ara-G on DNA synthesis
Cells were incubated for 2.5 hours with the indicated concentrations of ara-G followed by the addition of [ 3 H]-thymidine (2 µCi/mL) (Moravek Biochemicals, Brea, CA). DNA synthesis was measured using a MultiScreen assay system (Millipore Corp., Bedford, MA) as described 29 .
Determination of ara-GMP incorporation into DNA
The cells were incubated with varying concentrations of [8, 3 H]-ara-G (Moravek Biochemicals) for 3 h, washed with PBS and the DNA was isolated 33 . The amount of ara-GMP incorporated into DNA was determined by scintillation counting (Packard Instrument Co., Meridian, CT).
To determine the location of the ara-GMP in DNA, the cells were incubated either with 1, 
Analyses of Fas and FasL gene expression
RNA was extracted from ara-G treated CEM and Jurkat cells 35 . The levels of Fas and FasL expression were measured using a TaqMan real-time RT-PCR assay on an ABI Prism 7700 and 7900 Sequence Detection system (Applied Biosystems, Foster City, CA). Gene expression levels were measured in 200 ng of RNA using Predeveloped Assay Reagents for Fas and FasL as described by the manufacturer (Applied Biosystems) and the relative quantities were calculated using standard curves generated from known dilutions of doxorubicin treated CEM cell RNA 36 and normalized to endogenous GAPDH mRNA levels. The GAPDH specific probe and primer were as follows: Forward Primer 5'-GAAGGTGAAGGTCGGAGT-3'; Reverse
Effect of Fas-antagonist or Fas-agonist on ara-G-induced cell-death
Cells were incubated with 1 µg/ml ZB4 Fas-antagonist antibody for 1 h and then incubated with 100 µM ara-G for an additional 3 h. ZB4 alone and untreated cells served as negative controls.
Positive controls included 10 µg/ml CH-11 Fas-agonist antibody for 24 h or 10 µM ara-C for 4 h.
Cells were analyzed by flow cytometry for cell-cycle and apoptosis using the TUNEL assay kit, 
Cell-cycle analysis
Aliquots of untreated and ara-G treated cells were pelleted, fixed in ice cold 70% ethanol, stained with prodpidium iodide (PBS containing 0.5 % Tween 20, 15 µg/ml propidium iodide, and 5 µg/ml DNase-free RNase) and analyzed by flow cytometry (FACSCalibur, BD CellQuestPro v4.0, Becton Dickinson).
Statistical analysis
The accumulation and elimination kinetics of ara-GTP was determined using GraphPad Prism (GraphPad Software, Inc., San Diego, CA). The Kolmogorov-Smirnov (K-S) statistic was used for all flow analyses to compare mean intensity fluorescence to determine significance. Values greater than 0.16 were considered significant. For sFas ligand levels, the values in untreated versus treated cells were compared using student's one-tailed t-test. The statistical significance of changes in gene expression levels was determined using Prism software to perform a two tailed, unpaired t-test.
Results
T-cell specific cytotoxicity of ara-G
To gain insight into the mechanism of ara-G mediated cytotoxicity and T-cell selectivity, the leukemic cell lines CEM, Raji, and ML-1 were used to the represent T-, B-lymphoid, and myeloid lineages, respectively. Three separate tests demonstrated T-cell selectivity of ara-G in these cells. First, cell proliferation assay suggested T-lymphoblastic CEM cells are the most sensitive to the effects of ara-G (Fig. 1A) . The IC 25 for CEM was 3 µM whereas for Raji, and ML-1 it was 300 µM. The second method, the MTS assay (Fig. 1B ) resulted in findings similar to the cell growth inhibition assay, as CEM were the most sensitive with an IC 25 and IC 50 of 3 µM and 30 µM, respectively while 300 µM appeared to be the IC 50 and IC 25 for Raji and ML-1, respectively. Finally, clonogenicity measurements demonstrated that in CEM cells there is a rapid loss of clonogenicity even at low concentrations of ara-G (Fig. 1C ). For instance, under these conditions, there was a 25% loss of clonogenicity in this cell line at 0.1 µM ara-G; IC 50 was less than 10 µM. In contrast, an IC 50 was not achieved in Raji or ML-1 cells despite incubations of up to 300 µM ara-G. T-cell selectivity was also observed when other cell lines, such as MOLT-4, were used (data not shown).
Accumulation and elimination kinetics of ara-GTP
To determine if the observed differential cytotoxicity in model cell lines was related to the levels of ara-GTP, the concentration and time dependent accumulation of ara-GTP was compared. In CEM cells, incubation with up to 300 µM ara-G resulted in a proportional increase in ara-GTP accumulation. In B-lineage Raji or myeloid ML-1, the accumulation of ara-GTP was a log order lower ( Fig. 2A) . The accumulation appeared to saturate by 100 µM in Raji and was never higher than 20 µM at any concentration tested in ML-1.
To determine if the rate of ara-GTP was linear with time, cell lines were incubated with 100 µM ara-G for up to 12 h (Fig. 2B ). This concentration of ara-G was selected because at the maximally tolerated dose of nelarabine, patients achieved a median 116 µM plasma ara-G concentration 21 . The rate of ara-GTP accumulation in CEM cells was 60 µM/h and remained linear for up to 12 h. The initial rate (0 -2 h) in Raji cells was approximately 30 µM/h but was saturated by 2 h and after 8 h the intracellular ara-GTP concentration was 60 µM. In myeloid
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Previous work investigating the differential cytotoxicity to ara-G has suggested that Bcells eliminate ara-GTP more rapidly than T-cells 20 . Although the accumulation of ara-GTP was different among these cell lines, all three cell lines demonstrated prolonged retention of ara-GTP (Fig. 2C) . After a 3-h incubation with 100 µM ara-G, the data in CEM demonstrated a biphasic elimination of ara-GTP. The initial elimination (t 1/2 ) was rapid and lasted approximately 60 min. The terminal elimination (t 1/2 ) was prolonged (>24 h). The kinetics in B-lymphoid Raji and ML-1 myeloid cells was also biphasic and showed a prolonged retention of ara-GTP with terminal half-life of >24 h.
Ara-G induced DNA synthesis inhibition
In order to determine if differential accumulation of ara-GTP reflects on ara-G-mediated inhibition of DNA synthesis, the thymidine incorporation assay was employed. All three cell lines have a dose dependent decrease in thymidine incorporation; however, the extent of inhibition was different (Fig. 3) . The IC 50 for CEM is approximately 1 µM and greater than 90% inhibition of thymidine incorporation is evident at 30 µM. Raji and ML-1, on the other hand, are less sensitive; with an IC 50 of approximately 300 µM. There was no effect on RNA and protein synthesis by ara-G (data not shown) indicating that DNA was the primary target.
Incorporation of ara-GMP into DNA
Previously we have demonstrated that the incorporation of ara-G nucleotide into DNA is critical for its cytotoxic effects 29 . To test if the differential cytotoxicity was related to the number of ara-G moieties in the DNA, the levels of ara-GMP in the DNA was quantitated (Table 1) . For all three cell lines, there was a dose-dependent increase in ara-GMP molecules in DNA. However, Taken together, the number of ara-GMP molecules into DNA is not a determinant for T-cell selective cytotoxicity.
While the absolute quantity of ara-GMP in DNA may not reflect its cytotoxic effect, the position of ara-GMP in DNA may be responsible for the observed differential sensitivity.
Because there are two types of linkages in a DNA strand, internal and terminal, were ara-GMP may be incorporated, we identified the position of ara-GMP in DNA in each cell type. HPLC analysis of nuclease digested DNA isolated from CEM, Raji, or ML-1 cells incubated with 100
3 H] ara-G 34 for 3 h showed that 89.9 ± 11.2, 89.9 ± 11.3, 89.6 ± 13.2% of the incorporated ara-GMP residues were detected as internal nucleotides, respectively . This was similar to the incorporation of [ 3 H]dAdo, which served as a positive control; which was 84.9 ± 14.9, 85.3 ± 15.6, 84.8 ± 15.2, respectively. Between 89 and 93 % internal incorporation was observed in each cell line at 1 and 10 µM ara-G. These findings strongly suggest that in whole cells, the DNA with incorporated ara-GMP is extended by DNA polymerases.
Cell-cycle distribution and apoptosis in response to ara-G
The number of ara-GMP molecules in DNA is dependent on the number of cells in S-phase. To determine the cell-cycle distribution in these cell lines, cells were incubated with ara-G and analyzed by flow cytometry ( Table 2 ). The cell-cycle profile was similar in untreated cells from
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all three lines but the distribution differently changed after ara-G treatment. In CEM cells, there was an increase in the sub-G 1 population from 3 to 32% between 0 and 24 h with a corresponding decrease in the S-phase fraction from 28 to 7 %. In contrast, Raji and ML-1 demonstrated approximately 2% sub-G 1 DNA content over the same time period with an increase in the percentages of S phase fraction from about 30 % to 60% indicative of S-phase arrest after drug treatment.
Up-regulation of Fas after ara-G treatment
The Fas/FasL pathway is associated with the deletion of cells of lymphoblasts and myeloblasts. an evaluation of soluble FasL in the medium (Fig. 4) . After 3-h incubation with 100 µM ara-G, a significant 2-fold increase in sFasL in the medium of CEM cells (P=0.03) was detected by ELISA. After 24 h, the level remains elevated over that seen in control, but this value was not significant. In contrast, neither Raji nor ML-1 showed an increase in sFasL in the medium at any time during the incubation.
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Ara-G induces an increase in Fas and FasL gene expression
To determine if the ara-G mediated-increase in the FasL protein in CEM cells is related to changes in its gene expression, the levels of FasL and Fas mRNA were assessed by TaqMan real-time RT-PCR. The analysis of FasL mRNA levels consistently displayed a significant spiked increase in gene expression which peaked one hour after ara-G treatment (Fig. 5A,   P=<0 .0001, n = 20). The amount of FasL mRNA returned to control levels by 1.5 hr of treatment (P=0.78, n=8) and remained at this level for at least six hours of treatment (2 
Role of FasL in T -cell selective cytotoxicity
To test if the increase in the sFasL transcript and protein levels could play a role in ara-G mediated T-cell selective cytotoxicity, cells were treated with 100 µM ara-G for 3 h in the 
Discussion
Our model system cell lines demonstrated T-cell selective cytotoxicity with ara-G (Fig. 1) . . As observed previously in primary leukemia cells in vitro 16 and in phase I studies 21 , the accumulation of ara-GTP is greatest in cells of T-lymphoid lineage (Fig. 2) 9,18 . These data and the fact that ara-GTP levels are strongly related to response to nelarabine therapy suggest that triphosphate accumulation is one of the determinants for lineage-specific cytotoxicity. However, Our previous work clearly demonstrated the requirement of ara-G incorporation into DNA for cell-death 29 . Therefore, we tested if the number of ara-G residues in DNA was greater in Tcells compared to other cell lineages. Surprisingly, the CEM cell line, which was most sensitive to ara-G, incorporated the least number of ara-G molecules but had the greatest inhibition of DNA synthesis. In contrast, Raji and ML-1 accumulated greater amount of ara-GMP in the DNA with lesser inhibition of DNA synthesis and cell-death (Table 1) . Although, within a cell line ara-G incorporation into DNA appears to play a role in dose-dependent inhibition of DNA synthesis or cellular toxicity, between cell lines such correlation does not exist.
Because the incorporation of ara-GMP into DNA occurs only during the S-phase, we sought to determine the dynamics of cell-cycle distribution after ara-G treatment. Although the cell-cycle distribution was similar in untreated cells, after treatment the proportion of S-phase cells dramatically decreased in CEM but increased in Raji and ML-1 cell lines (Table 2 ). This increase in the S-phase percentage will amplify the number of incorporated ara-GMP molecules of the whole population. Hence, we recalculated the number of ara-G(DNA) by normalizing with the S-phase population. Even after this normalization, the number of ara-G residues was not greater in CEM cells; at 100 µM ara-G, the numbers were 53, 71, and 48 pmoles/mg of Sphase DNA in CEM, Raji, ML-1 cells, respectively. Taken together, these observations suggest that there are additional parameters responsible for differential cytotoxicity.
In vitro DNA primer extension assays using purified DNA polymerases have established termination of DNA synthesis after ara-GMP incorporation. It is feasible that greater number of
ara-GMP in the terminal position may reflect on inhibition of DNA synthesis leading to celldeath. Hence, we quantitated the ara-G residues at terminal versus internal position in these cell lines. Similar to dAMP incorporation, majority of ara-GMP molecules were found in the internal linkage in the three model cell lines. Clearly, this internucleotide incorporation of ara-G does not play a role for T-cell specific sensitivity.
As described above, similar number of ara-GMP molecules per S-phase cells in internal linkage results in separate consequences in T-versus non-T-cell types. In T-cells, this event was lethal while in non-T-cells, this incorporation was associated with S-phase arrest. This arrest may be transient and represent cell-cycle checkpoint initiated to repair the damage caused by ara-GMP molecules in DNA. In such a scenario, if the drug is removed, cells may repair DNA and proceed with a transit through S-phase and normal proliferation rate. Our Raji and ML-1 cloning data (Fig. 1C) suggest that this postulate is correct because there was only a minimal loss of colony formation capability of these cells after a 3-h ara-G treatment.
An additional possibility exists for the resistance of non-T-cells to ara-G. This could be due to up-regulation of survival pathways, increased levels of antiapoptotic proteins, or inherent attenuation of cell-death pathways. In such a case, these cells would be resistant to other nucleoside analogues. However, these cells were hypersensitive to many purine and pyrimidine analogues such as gemcitabine, ara-C, and fludarabine 24, 42, 43 . Furthermore, molecules such as p53 that has been shown to be involved in various forms of apoptosis induced by cellular "stress" 44 was not a factor in our experimental systems. The p53 is heterozygous mutated in CEM 45 and Raji 46 while ML-1 is p53 wild-type 47 suggesting that p53 is not a component of the observed ara-G selectivity.
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The mitochondria have been implicated in driving the apoptotic cascade by releasing cytochrome c from the intermembrane space, to the cytoplasm. After release, cytochrome c binds to Apaf1 in the presence of dATP and this complex (the apoptosome) then activates a caspase cascade with caspase 9 at its apex 48, 49 . Recently, it has been shown that ara-GTP can substitute for dATP in an in vitro assay system using cytochrome c and Apaf1 proteins 50 . The K m value of ara-GTP in this reaction is ~200 µM. In T cells, the intracellular level of ara-GTP is greater than 250 µM, suggesting that in whole cells, ara-GTP molecules may substitute for dATP in apoptosome. Such mechanism may amplify the death signal, however the initial trigger for apoptosis in response to ara-G occurs only after incorporation of ara-GMP into DNA.
There is evidence for an active role of the Fas/FasL system in the process of drug-induced apoptosis including nucleoside analogues 36, [51] [52] [53] [54] [55] [56] [57] [58] (Fig. 4) . This was preceded by a transient but consistent increase in transcript level of FasL (Fig. 5A ). This finding suggested a role for soluble FasL in the observed T-cell hypersensitivity to ara-G. Prompted by our previous data 63 , Mansson et al. 64 further confirmed involvement of the Fas pathway in ara-G mediated T-cell cytotoxicity by demonstrating a 3-6 fold reduction in
Fas protein levels and no detectable levels of Fas mRNA in ara-G resistant T-cell lines. An important feature of Fas-mediated apoptosis is the mechanism of autocrine suicide or paracrine death initially described for activated T-cells 40 . The data from the TUNEL assay demonstrate Ara-G induced T-cell selective cytotoxicity 18 that by 6 h, ara-G is able to induce apoptosis in CEM from all phases of the cell cycle. When ZB4 is added to CEM cells prior to the addition of ara-G, only S phase cells remain susceptible to ara-G-induced apoptosis. This suggests that the T-cell selective cytotoxicity observed in CEM is due to ara-G incorporation into the DNA of S-phase cells, stimulating the release of sFasL into the medium (Fig. 4) , and triggering death receptor mediated cell-death in the by-stander cells (Fig. 6 ). This mechanism of action might also explain the selectivity observed in immature Tcells both in vitro and in vivo. Under these conditions, cell killing was blocked only ~30% by FasL neutralizing antibodies and required anti-TNF-antibodies to achieve a high degree of apoptosis inhibition. Because apoptosis was blocked by >85% with FasL neutralizing antibodies in our system and primarily only an S-phase cytotoxicity remains, suggests the activation of other death receptor pathways may not play a major role in ara-G mediated cell killing.
In conclusion, the present study illustrates that several factors are responsible for ara-G induced cytotoxicity in T-cell lineage. First, the pharmacokinetics of ara-GTP accumulation is favorable resulting in higher levels of ara-GTP. Second, incorporation of this fraudulent nucleotide into replicating DNA initiates S-phase specific cell-death. Third, the signal for apoptosis may be enhanced by cytosolic ara-GTP by binding to the apoptosome complexes.
Finally, the transcriptional and translational up-regulation of sFasL may account for S-phase (middle panels), and ML-1 (lower panels) were either untreated or treated with ZB4, the Fasantagonist antibody ; ara-G; ZB4 for 1 h followed by ara-G; or CH-11, the Fas-agonist antibody.
Cells were analyzed by flow cytometry for TUNEL positivity and their cell-cycle profile.
